偏头痛
医学
降钙素基因相关肽
替代医学
偏头痛治疗
精神科
重症监护医学
内科学
神经肽
病理
受体
出处
期刊:PubMed
日期:2019-01-01
卷期号:25 (2 Suppl): S23-S34
被引量:87
摘要
Migraine is a leading cause of disability worldwide. Approximately 15% of Americans experience migraines. Most people who have migraines feel that people who do not have them often underestimate their condition. Migraines affect people's quality of life and ability to participate in work, family, and social events. A new class of medication, calcitonin gene-related peptide (CGRP) antagonists, has been approved for migraine prevention in adults. The newly approved CGRP antagonists are erenumab, fremanezumab, and galcanezumab, while eptinezumab looks to 2020 for approval. Lasmiditan, ubrogepant, and rimegepant are currently emerging acute migraine therapies that may be added to the arsenal of current migraine management.
科研通智能强力驱动
Strongly Powered by AbleSci AI